©2024 Stanford Medicine
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
Recruiting
I'm InterestedTrial ID: NCT02502162,,
Purpose
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of
complex regional pain syndrome (CRPS). Study participants will be randomly assigned to
receive either LDN or placebo for a period of several weeks. During this period participants
will be asked to attend either in-person or virtual study visits and complete questionnaires.
Official Title
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
Stanford Investigator(s)
Sean Mackey, M.D., Ph.D.
Redlich Professor, Professor of Anesthesiology, Perioperative, and Pain Medicine and, by courtesy, of Neurology
Eligibility
Inclusion Criteria:
- Upper and/or lower extremity CRPS
- On stable treatment for 1 month
- CRPS for at least 1 year
- Meet the Budapest criteria for CRPS at time of the study.
Exclusion Criteria:
- Any known allergy to naltrexone or naloxone
- Use of prescription opioid analgesics or illegal opioid use
- Current or planned pregnancy.
Intervention(s):
drug: LDN
drug: Placebo
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Birute Gedrimaite
650-497-0485